암 면역치료 시장은 2025년 1,678억 6,200만 달러에서 2030년에는 3,412억 7,300만 달러까지 CAGR 15.25%를 나타낼 것으로 예측됩니다.
암 면역치료 시장은 암 이환율 증가와 암세포와 싸우기 위해 신체의 면역 시스템을 이용하는 치료법의 진보에 의해 강력한 성장을 이루고 있습니다. 면역치료는 자연적인 방어 기구를 활용하여 암을 식별·제거하고, 종래의 방법에 비해 독성을 저감한 표적 치료 옵션을 제공합니다. 시장은 연구개발에 대한 많은 투자, 선진요법의 채용 확대, 암에 대한 의식 증가에 의해 지원되고 있습니다. 그러나 높은 치료비와 긴 규제 당국의 승인 과정이 시장 확대의 과제가 되고 있습니다. 이러한 과제에도 불구하고 이 시장은 특히 헬스케어 인프라가 갖추어져 있는 지역과 암 이환율이 상승하고 있는 신흥국에서 지속적인 성장이 예상되고 있습니다.
주요 성장 요인
고급 면역치료에 대한 투자
암 면역치료 시장은 주요 제약 회사와 연구 기관에 의한 많은 투자에 의해 지원됩니다. 이러한 투자는 체크포인트 억제제 및 CAR-T 세포 요법과 같은 효능을 높이고 부작용을 최소화하는 표적 면역치료의 개발에 중점을 둡니다. 업계 리더간의 협력 체제가 신약의 개발을 가속화하고, 암 치료에 있어서의 미충족 요구에 대응하고, 환자의 결과를 개선하는 것으로 시장의 성장을 가속하고 있습니다.
폐암 이환율 상승
흡연이나 환경 노출 등의 요인에 의한 폐암 이환율 증가는 시장 성장에 크게 기여하고 있습니다. 폐암은 세계적으로 이환율이 높기 때문에 면역치료 시장에서 큰 점유율을 차지하고 있습니다. 신흥경제국에서의 고액의 헬스케어 지출이나 효과적인 치료법의 연구개발에 뒷받침된 면역치료의 채용은 특히 폐암 특이적인 치료법 수요를 더욱 촉진할 것으로 예측됩니다.
The global cancer immunotherapy market is expected to grow from USD 167.862 billion in 2025 to USD 341.273 billion in 2030, at a CAGR of 15.25%.
The global cancer immunotherapy market is experiencing robust growth, driven by the increasing prevalence of cancer and advancements in therapies that harness the body's immune system to combat cancer cells. Immunotherapy leverages natural defense mechanisms to identify and eliminate cancer, offering targeted treatment options with reduced toxicity compared to traditional methods. The market is propelled by significant investments in research and development, growing adoption of advanced therapies, and rising cancer awareness. However, high treatment costs and lengthy regulatory approval processes pose challenges to market expansion. Despite these hurdles, the market is poised for continued growth, particularly in regions with strong healthcare infrastructure and emerging economies with rising cancer incidences.
Key Growth Drivers
Investments in Advanced Immunotherapies
The cancer immunotherapy market is bolstered by substantial investments from major pharmaceutical companies and research organizations. These investments focus on developing targeted immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, which enhance efficacy and minimize side effects. Collaborative efforts among industry leaders are accelerating the development of novel drugs, driving market growth by addressing unmet needs in cancer treatment and improving patient outcomes.
Rising Incidence of Lung Cancer
The increasing prevalence of lung cancer, driven by factors such as smoking and environmental exposures, significantly contributes to market growth. Lung cancer holds a substantial share of the immunotherapy market due to its high global incidence. The adoption of immunotherapies, supported by high healthcare expenditure in developed economies and ongoing research into effective treatments, is expected to further propel demand, particularly for lung cancer-specific therapies.
Market Segmentation
By Application
The cancer immunotherapy market is segmented into skin cancer, lung cancer, leukemia, bladder cancer, and others. Lung cancer dominates due to its high prevalence and the growing adoption of immunotherapies in regions with strong healthcare systems. Bladder cancer and leukemia also hold significant shares, driven by increased research and development investments targeting these cancer types, which require specialized immunotherapeutic approaches to improve patient outcomes.
By Geography
The market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. North America is expected to maintain a significant market share, driven by early adoption of innovative therapies, a high prevalence of cancer, and substantial R&D investments. The presence of key market players and a robust regulatory framework, including FDA approvals for immunotherapy drugs, further supports growth. Asia-Pacific is projected to experience rapid growth, fueled by an increasing cancer patient pool, rising awareness, and technological advancements in countries like India and China, where clinical trials for therapies like CAR-T are expanding.
Competitive Landscape
Key players, including Bristol-Myers Squibb Company, Eisai Co., Ltd., Nektar, and Servier, are driving innovation through collaborative research and development of advanced immunotherapies. These companies focus on novel drug combinations and targeted therapies to enhance treatment efficacy and expand market reach.
The cancer immunotherapy market is set for significant growth, propelled by rising cancer incidences, particularly lung cancer, and substantial investments in advanced therapies. North America leads due to its strong healthcare infrastructure, while Asia-Pacific's rapid expansion reflects growing patient needs and clinical advancements. Despite challenges like high costs and regulatory delays, the market's trajectory remains positive, driven by ongoing innovation and the critical role of immunotherapy in transforming cancer treatment.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Segmentation:
The global cancer immunotherapy market has been analyzed through the following segments: